Genomic Health (FRA:G7H) Change In Receivables : €-3.9 Mil (TTM As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Genomic Health Change In Receivables?

Genomic Health's change in receivables for the quarter that ended in Sep. 2019 was €-1.4 Mil. It means Genomic Health's Accounts Receivable increased by €1.4 Mil from Jun. 2019 to Sep. 2019 .

Genomic Health's change in receivables for the fiscal year that ended in Dec. 2018 was €-5.5 Mil. It means Genomic Health's Accounts Receivable increased by €5.5 Mil from Dec. 2017 to Dec. 2018 .

Genomic Health's Accounts Receivable for the quarter that ended in Sep. 2019 was €50.7 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Genomic Health's Days Sales Outstanding for the three months ended in Sep. 2019 was 44.59.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Genomic Health's liquidation value for the three months ended in Sep. 2019 was €187.3 Mil.

Genomic Health Change In Receivables Historical Data

The historical data trend for Genomic Health's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Change In Receivables Chart

Genomic Health Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Receivables

Get a 7-Day Free Trial

-4.44

-2.06

1.88

3.40

-5.49

Genomic Health Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Change In Receivables	Get a 7-Day Free Trial															-2.20	0.02	-6.83	4.37	-1.42

Genomic Health Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.9 Mil.

Genomic Health (FRA:G7H) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Genomic Health's Days Sales Outstanding for the quarter that ended in Sep. 2019 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	50.735	/	103.834	*	91
=	44.59

2. In Ben Graham's calculation of liquidation value, Genomic Health's accounts receivable are only considered to be worth 75% of book value:

Genomic Health's liquidation value for the quarter that ended in Sep. 2019 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	250.095	-	100.823	+	0.75 * 50.735	+	0.5 * 0
=	187.3

Genomic Health Change In Receivables Related Terms

Thank you for viewing the detailed overview of Genomic Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomic Health (FRA:G7H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Penobscot Drive, Redwood City, CA, USA, 94063

Website

http://www.genomichealth.com

Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines